Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Dec;60(12):1012-8.
doi: 10.1136/thx.2005.045260. Epub 2005 Sep 15.

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

Affiliations

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

P H Howarth et al. Thorax. 2005 Dec.

Abstract

Background: Tumour necrosis factor alpha (TNFalpha) is a major therapeutic target in a range of chronic inflammatory disorders characterised by a Th1 type immune response in which TNFalpha is generated in excess. By contrast, asthma is regarded as a Th2 type disorder, especially when associated with atopy. However, as asthma becomes more severe and chronic, it adopts additional characteristics including corticosteroid refractoriness and involvement of neutrophils suggestive of an altered inflammatory profile towards a Th1 type response, incriminating cytokines such as TNFalpha.

Methods: TNFalpha levels in bronchoalveolar lavage (BAL) fluid of 26 healthy controls, 42 subjects with mild asthma and 20 with severe asthma were measured by immunoassay, and TNFalpha gene expression was determined in endobronchial biopsy specimens from 14 patients with mild asthma and 14 with severe asthma. The cellular localisation of TNFalpha was assessed by immunohistochemistry. An open label uncontrolled clinical study was then undertaken in 17 subjects with severe asthma to evaluate the effect of 12 weeks of treatment with the soluble TNFalpha receptor-IgG1Fc fusion protein, etanercept.

Results: TNFalpha levels in BAL fluid, TNFalpha gene expression and TNFalpha immunoreative cells were increased in subjects with severe corticosteroid dependent asthma. Etanercept treatment was associated with improvement in asthma symptoms, lung function, and bronchial hyperresponsiveness.

Conclusions: These findings may be of clinical significance in identifying TNFalpha as a new therapeutic target in subjects with severe asthma. The effects of anti-TNF treatment now require confirmation in placebo controlled studies.

PubMed Disclaimer

Comment in

  • Etanercept in chronic severe asthma.
    Oliveri C, Polosa R. Oliveri C, et al. Thorax. 2006 Jul;61(7):640; author reply 640. Thorax. 2006. PMID: 16807393 Free PMC article. No abstract available.

Similar articles

Cited by

References

    1. Eur Respir J. 1999 Oct;14(4):902-7 - PubMed
    1. J Allergy Clin Immunol. 2000 Dec;106(6):1033-42 - PubMed
    1. N Engl J Med. 2001 Jan 4;344(1):30-7 - PubMed
    1. Immunol Cell Biol. 2001 Apr;79(2):132-40 - PubMed
    1. Am J Respir Crit Care Med. 2001 Sep 1;164(5):744-8 - PubMed

Publication types